

Successful Completion of VentrAssist BTT Trial

Sydney AUSTRALIA 12 March 2009: Ventracor Limited (ASX:VCR) reported today that the US Bridge To Transplant (BTT) Trial of the VentrAssist[®] Left Ventricular Assist Device (LVAD) has reached a successful completion.

The Data and Safety Monitoring Board (DSMB) met to review the clinical data, and concluded that the VentrAssist LVAD has met the performance goal in the BTT Trial. Furthermore, adverse event rates were reviewed by the DSMB, and were felt to be consistent with the published rates for similar populations and devices, and markedly improved over first generation pulsatile LVADs.

Based on the interim analysis of 98 patient outcomes, the trial showed 78.6% success to the trial definition of the target outcome of survival to heart transplantation or listing for heart transplantation at 180 days. Review of all patients implanted showed that 85% were transplanted or alive on support at 6 months, and 82% were transplanted or alive on support at 12 months. There was a statistically and clinically significant improvement in Quality of Life test scores and functional status over time.

Dr. Andrew Boyle, the Cardiology Principal Investigator for the BTT Trial, will present the clinical results at the Late Breaking Clinical Trial Session of the annual scientific meeting of the American College of Cardiology on 29 to 31 March 2009 in Orlando, Florida.

Ventracor's Chief Executive Officer, Mr Peter Crosby, said: "This is an outstanding achievement by the whole team, and we especially thank the physician investigators, and the patients, who participated in this trial. We are proud that the VentrAssist LVAD is the first centrifugal pump, and the first third generation pump, to have successfully completed a clinical trial in the US. We look forward to compiling the results ready for an application to the US FDA for Pre-Market Approval."

About Ventracor

Ventracor is a global medical device company which produces an implantable blood pump, the VentrAssist[®] left ventricular assist device (LVAD), as therapy to improve the lives of heart failure patients and their families. Ventracor is dedicated to building partnerships with healthcare professionals to make the VentrAssist LVAD the standard-of-care worldwide.

For further information, please contact: Graeme Fallet CFO, or Angela Edwards, Investor Relations Tel: +61(2)94063100 or visit www.ventracor.com